CH31 and CH33 are B cell lymphomas whose growth in vitro is inhibited by anti-Ig reagents, including both polyclonal and monoclonal anti-mu antibodies, and an anti-idiotype antiserum. Antibodies against class I or class II major histocompatibility complex antigens do not affect the growth of these cells. Inhibition is dependent on surface Ig cross-linking and does not require ligand binding to Fc receptors. Interestingly, the inhibition of growth by anti-mu is reversed in CH31 (but not CH33) by E. coli lipopolysaccharide. These lymphomas should provide excellent models to study the mechanisms of growth inhibition mediated by surface Ig cross-linking and the pathways of its reversal.
No takes yet. Share an insight, caveat, or question.
Pennell et al. (1986) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: